by Nicolas Oberndorfer | Apr 13, 2021 | Dermapharm Corporate News, News
Corporate news to the archive Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures Revenue and earnings up due to organic growth and successful acquisitions Vaccine production to commence in May 2021 at Allergopharma’s site...
by Nicolas Oberndorfer | Feb 16, 2021 | Dermapharm Corporate News, News
Corporate news to the archive Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021 Grünwald, February 12, 2021 – Dermapharm Holding SE...
by Nicolas Oberndorfer | Nov 16, 2020 | Dermapharm Corporate News, News
Corporate news to the archive Dermapharm Holding SE continues on its growth course in third quarter of 2020 Group revenue rose by 11.5% to EUR 577.2 million Adjusted Group EBITDA increased by 4.4% to EUR 139.0 million; corresponding adjusted EBITDA margin at...
by Nicolas Oberndorfer | Sep 10, 2020 | Dermapharm Corporate News, News
Corporate news to the archive Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine Grünwald, September 10, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded...
by Nicolas Oberndorfer | Sep 9, 2020 | Dermapharm Corporate News, News
Corporate News back to archive Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic Group revenue up 14% year-on-year to EUR 378 million Adjusted EBITDA of EUR 92 million around 2% above previous year’s level Forecast...
by Nicolas Oberndorfer | Aug 21, 2020 | Dermapharm Corporate News, News, Uncategorized
Corporate news to the archive Dermapharm remains on growth course despite corona pandemic in the first half of 2020 Group revenue up 14% year-on-year to EUR 378 million Adjusted EBITDA of EUR 92 million around 2% above previous year’s level Allergopharma consolidated...
